Dendritic Cell Therapy

  title={Dendritic Cell Therapy},
  author={Farhad Dastmalchi and Aida Karachi and Duane A. Mitchell and Maryam Rahman},
3 Citations
Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy
The metabolic changes induced during activation of an immune response, and the role of metabolic profiling to monitor immune responses in the context of immunotherapy for malignant brain tumors are discussed.
Immunotherapy for Treatment of Cancer
  • A. Karachi
  • Medicine
    Current Trends in Cancer Management
  • 2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
Sarcosine increases the migration of murine and human DCs via the CXC chemokine pathway and can be utilized to improve existing DC vaccine strategies.


Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial)
Immunotherapy with IFN-DCs was safe and elicited HCV-specific T cell responses which were insufficient to eliminate viruses but could be implicated in the restriction of viral replication.
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
A phase-II clinical trial of autologous DCs vaccination in patients with newly diagnosed patients GBM who were candidates to complete or near complete resection suggests that the addition of tumor lysate-pulsed autologueous dendritic cells (DCs) vaccination to maximal safe resection and combined radio-chemotherapy is feasible and safe.
Advances and challenges: dendritic cell vaccination strategies for glioblastoma
Current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injectingdendritic cells to achieve maximal anti-tumor efficacy in glioblastoma are discussed.
CD103+ Dendritic Cell Function Is Altered in the Colons of Patients with Ulcerative Colitis
In patients with UC, CD103+ DCs show the impaired ability to generate Treg cells, but exhibit a colitogenic function inducing Th1/Th2/Th17 responses, showing how human CD103+, HLA-DRhighCD14−CD103− cells could contribute to the pathogenesis of UC.
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Vaccination of patients with AML with WT1 mRNA-electroporated DCs can be an effective strategy to prevent or delay relapse after standard chemotherapy, translating into improved OS rates, which are correlated with the induction of WT1-specific CD8+ T-cell response.
Dendritic cell-based immunotherapy: a basic review and recent advances
This review will hold focus on DC immunobiology, on the new concept of cancer immunoediting, and on the knowledge given by clinical trials using DC vaccines, as well as applying the latest advances in science.
Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia
The feasibility, safety, immunogenicity, and therapeutic potential of human telomerase reverse transcriptase expressing autologous dendritic cells (hTERT‐DCs) in adult patients with AML are evaluated.
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
It is indicated that intratumoral administration of proinflammatory allogeneic DCs induces an anti-tumor immune response that may prolong survival in unfavourable risk mRCC-patients given subsequent standard of care.
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Despite increased Treg proportions following DI-TMZ, patients receiving pp65-DCs showed long-term PFS and OS, confirming prior studies targeting cytomegalovirus in glioblastoma.